<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2012-723</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-408</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Синдром фибромиалгии: можно ли добиться улучшения?</article-title><trans-title-group xml:lang="en"><trans-title>Fibromyalgia syndrome: Can improvement be achieved?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чичасова</surname><given-names>Наталья Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Chichasova</surname><given-names>Natalia Vladimirovna</given-names></name></name-alternatives><bio xml:lang="ru"><p>Department of Rheumatology, Faculty for Postgraduate Training of Physicians</p></bio><bio xml:lang="en"><p>Department of Rheumatology, Faculty for Postgraduate Training of Physicians</p></bio><email xlink:type="simple">kafedraRheum@yandex.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иголкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Igolkina</surname><given-names>E V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>06</month><year>2012</year></pub-date><volume>6</volume><issue>2</issue><issue-title>№2 (2012)</issue-title><fpage>16</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чичасова Н.В., Иголкина Е.В., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Чичасова Н.В., Иголкина Е.В.</copyright-holder><copyright-holder xml:lang="en">Chichasova N.V., Igolkina E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/408">https://mrj.ima-press.net/mrj/article/view/408</self-uri><abstract><p>Представлены данные о распространенности, патогенезе, клинических проявлениях и лечении синдрома фибромиалгии (ФМ). Указано, что при лечении больных ФМ следует учитывать соотношение всех клинических симптомов заболевания. Лечение таких больных должно проводиться при участии различных специалистов. При преобладании психологических расстройств показаны психотропные препараты, которые назначает психиатр, длительность такой терапии вариабельна, но, как правило, не превышает 2—3 мес. Большинство больных нуждаются в надежном обезболивании, улучшении качества и продолжительности сна, уменьшении утомляемости, которая нередко приводит к снижению (или утрате) трудоспособности. Прегабалин (лирика) быстро подавляет основные проявления ФМ — начало эффекта отмечается уже через 1 нед лечения, эффективную и безопасную терапию этим препаратом можно продолжать длительное время.</p></abstract><trans-abstract xml:lang="en"><p>Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow The paper gives data on the prevalence, pathogenesis, clinical manifestations, and treatment of fibromyalgia (FM) syndrome. It is stated that the ratio of all clinical symptoms of FM syndrome should be borne in mind when treating patients with this disease. Various specialists should be attracted to the treatment of these patients. Psychotropic medications that are prescribed by a psychiatrist are indicated where there is a preponderance of psychological disorders; the duration of this therapy is variable, but not more than 2—3 months. Most patients need proper analgesia, improved sleep quality and duration, and diminished fatigability that frequently leads to lower (none) working capacity. Pregabalin (lyrica) promptly suppresses the major manifestations of FM; the onset of its action is seen just after one week of treatment; the use of the drug may be continued as long as it is effective and safe.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фибромиалгия</kwd><kwd>патогенез</kwd><kwd>клинические проявления</kwd><kwd>психологические нарушения</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>fibromyalgia</kwd><kwd>pathogenesis</kwd><kwd>clinical manifestations</kwd><kwd>psychological disorders</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
